Assenagon Asset Management S.A. Has $46.87 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Assenagon Asset Management S.A. boosted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 20.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 155,695 shares of the biopharmaceutical company's stock after purchasing an additional 26,799 shares during the quarter. Assenagon Asset Management S.A. owned 0.12% of Alnylam Pharmaceuticals worth $46,869,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. Norges Bank bought a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $895,816,000. Qube Research & Technologies Ltd acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $369,943,000. AQR Capital Management LLC raised its holdings in Alnylam Pharmaceuticals by 295.2% in the 3rd quarter. AQR Capital Management LLC now owns 744,008 shares of the biopharmaceutical company's stock valued at $336,009,000 after acquiring an additional 555,759 shares in the last quarter. Orbis Allan Gray Ltd lifted its position in shares of Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after acquiring an additional 486,489 shares during the period. Finally, Jacobs Levy Equity Management Inc. grew its holdings in shares of Alnylam Pharmaceuticals by 2,221.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 410,342 shares of the biopharmaceutical company's stock worth $187,116,000 after purchasing an additional 392,668 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

More Alnylam Pharmaceuticals News

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $455 price target. Although the firm lowered its 2026, 2028, 2029 and 2030 EPS forecasts, it raised its FY2027 estimate to $9.50 from $8.13, signaling expectations for continued longer-term earnings growth. HC Wainwright estimates for Alnylam Pharmaceuticals
• Neutral Sentiment: Several HC Wainwright revisions reduced projected EPS, including Q3 2026 to $1.65 from $1.79, Q4 2026 to $1.97 from $2.23, and FY2026 to $6.30 from $6.51. The firm’s estimates remain broadly positive beyond 2026, reaching $19.42 per share by FY2030, but the near-term reductions could limit enthusiasm. Alnylam Pharmaceuticals earnings estimates
• Neutral Sentiment: An AAII comparison examines whether Alnylam or Halozyme Therapeutics is the more attractive investment. The article may influence investor preferences, but it does not identify a new company-specific operating catalyst. Which Is a Better Investment, Alnylam Pharmaceuticals, Inc. or Halozyme Therapeutics, Inc. Stock?
• Neutral Sentiment: Options-market implied volatility for ALNY has surged, pointing to increased expectations for price movement and trading risk rather than a clear bullish or bearish fundamental signal. Implied Volatility Surging for Alnylam Pharmaceuticals Stock Options
• Negative Sentiment: Truist Financial lowered its price target on Alnylam to $315, a more cautious valuation view that could weigh on the stock and reflects concern about the company’s risk-reward profile. Truist Financial Lowers Alnylam Pharmaceuticals Price Target

Insider Activity

In related news, Director David E. I. Pyott sold 3,830 shares of the firm's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares of the company's stock, valued at $473,302.76. This trade represents a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company's stock.

Analyst Ratings Changes

A number of brokerages recently commented on ALNY. Royal Bank Of Canada decreased their price target on Alnylam Pharmaceuticals from $445.00 to $350.00 and set an "outperform" rating on the stock in a research report on Friday, July 31st. Stifel Nicolaus decreased their target price on shares of Alnylam Pharmaceuticals from $444.00 to $318.00 and set a "buy" rating on the stock in a report on Friday, July 31st. Raymond James Financial upgraded shares of Alnylam Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a $420.00 target price for the company in a research report on Monday, August 3rd. Barclays reduced their price target on shares of Alnylam Pharmaceuticals from $527.00 to $450.00 and set an "overweight" rating on the stock in a research report on Monday, August 3rd. Finally, Truist Financial decreased their price objective on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a "buy" rating on the stock in a research note on Tuesday, August 4th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and five have issued a Hold rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $396.72.

Alnylam Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ ALNY opened at $219.20 on Friday. The company has a market cap of $29.33 billion, a price-to-earnings ratio of 40.74 and a beta of 0.30. The company has a current ratio of 3.05, a quick ratio of 3.06 and a debt-to-equity ratio of 0.75. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The stock has a 50-day moving average price of $280.12 and a two-hundred day moving average price of $306.27.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source